Esperion eyes new commercial push for cholesterol-lowering drugs after big FDA label expansion
Esperion has secured major FDA label expansions for its two cholesterol-lowering drugs, a regulatory milestone that it says opens up a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
